Carcinoid Tumors of the Lung
For patients confronted with lung (pulmonary) carcinoid tumors, City of Hope offers customized care for each individual. Your treatment plan will be unique based on the characteristics of your disease and what quality of life means to you.
Less than 2% of lung cancers are carcinoids. According to the American Cancer Society, there are up to 4,000 newly diagnosed cases of lung carcinoid tumors in the United States each year.
Our team of talented, compassionate surgeons, medical oncologists, radiopharmacists and experts in nuclear medicine — among many more — work together seamlessly. And the options are leading-edge, from our excellence in minimally invasive surgery to imaging technology that helps our oncologists pinpoint the best treatment plan for each patient.
At City of Hope, we believe that patients deserve more, better options to control pulmonary carcinoid tumors.
When you come to City of Hope, you automatically gain access to an unparalleled array of support services to help you and your loved ones take each step during and after lung carcinoid tumor treatment.
Because lung carcinoid tumors are uncommon, it can be challenging to find the right help. City of Hope is a nationally recognized leader in the research and treatment of lung cancer and carcinoid tumors of the lung.
- We have specialists who regularly work with patients facing neuroendocrine tumors, keep pace with the latest developments in treatment and push forward state-of-the-art treatments through their innovative research.
- Our surgical expertise enables us to offer a more comprehensive array of options, including surgery for advanced disease and gentler robotic procedures.
- For more than a decade, U.S. News & World Report has named City of Hope one of the "Best Hospitals" for cancer in America.
- We bring together broad expertise from multiple specialties and are unmatched in our rapid "bench-to-bedside" record of translating leading-edge research into real-world treatments.
City of Hope is one of the few facilities designated a comprehensive cancer center by the National Cancer Institute.
Our developments in the areas of breakthrough cancer drugs, bone marrow transplants and CAR T cell therapy are recognized internationally.
Our leadership in research and innovation continually enhances our ability to provide novel and differentiated approaches to cancer care.
